An interventional study of Narrative Video Game in Alzheimer's Disease and Related Dementias and Advance Care Planning, sponsored by University of Pittsburgh. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alzheimer Disease by University of Pittsburgh — 2 open to participants now, 3 under way, none of them phase 3. Alzheimer Disease · University of Pittsburgh.
Among the 15 studies in Alzheimer Disease by University of Pittsburgh, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 11 with no phase, and was the 15th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 15 studies in Alzheimer Disease by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 86 across the 14 interventional studies, 81 across the 1 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pittsburgh is the lead sponsor of 1,421 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
2 of the studies in Alzheimer Disease by University of Pittsburgh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06565169University of PittsburghImproving PCP Advance Care Planning for People With ADRD | 2027-04-30 |
| NCT07940673University of PittsburghImproving Advance Care Planning by Care Partners of Persons Living With Dementia Using a Narrative Video Game | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Alzheimer Disease by University of Pittsburgh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the feasibility of using a narrative video game intervention to improve advance care planning (ACP) among care partners of people living with Alzheimer's Disease and Related Dementia. Feasibility will be assessed by evaluating acceptability as well as the fidelity of intervention delivery.
The trial is designed to establish the feasibility and plausibility of using the intervention to alter psychological outcomes, necessary to justify a future Type 1 hybrid effectiveness-implementation trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will complete the Surrogate ACP Readiness Survey prior to intervention exposure. Participants will schedule a video-conference visit with the research facilitator. During the session, they will be asked to use the intervention (ANTICIPATE), a narrative video game that asks users to rehearse making an end-of-life medical decision for a fictional character. The experience takes 20-30 minutes to complete. Immediately following intervention exposure, participants will be asked to complete the User Engagement Survey, the Acceptability, Appropriateness, and Feasibility Measures, and the Surrogate ACP Readiness Survey.
Behavioral: Narrative Video Game
Participants will schedule a video-conference visit with the research facilitator. During the session, they will be asked to use the intervention (ANTICIPATE), a narrative video game that asks users to rehearse making an end-of-life medical decision for a fictional character. The experience takes 20-30 minutes to complete. Immediately following intervention exposure, participants will be asked to complete the User Engagement Survey, the Acceptability, Appropriateness, and Feasibility Measures, and the Surrogate ACP Readiness Survey.
Behavioral: Narrative Video Game
The intervention (ANTICIPATE) is a narrative video game that asks users to rehearse making an end-of-life medical decision for a fictional character. The game begins with an introduction to the main character (Glenn), then proceeds to demonstrating loss of function secondary to progression of dementia, then describes Glenn as experiencing a serious illness and requiring intubation or palliation. The player, who has taken on the role of Glenn's daughter, must consider her father's preferences and functional status as she decides how to proceed.
Also known as: ANTICIPATE
Acceptability of the intervention (co-primary)
Proportion of participants who score the intervention as ≥4/5 on the Acceptability of Intervention Measure
Time frame: Immediately following intervention exposure
Fidelity of intervention delivery (co-primary)
Proportion of participants who complete all study tasks
Time frame: 3 months post-intervention exposure
Fidelity of intervention receipt
Mean responses to the items on the ACP Engagement Survey for Surrogate Decision makers and then summarized by domain (knowledge, readiness, self-efficacy, contemplation).
Time frame: Pre-intervention to 3 months post-intervention
Fidelity of intervention enactment (self-reported completion of ACP)
Proportion of participants who report ACP activities after intervention exposure
Time frame: 3 months post-intervention
Fidelity of behavior change technique delivery
Proportion of participants who report the use of behavioral rehearsal during the game or who demonstrate the use of rehearsal during game play.
Time frame: Immediately post-intervention
Plan to share: Yes — All collected and de-identified individual participant data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: It will be made available within 6 months of completion of the study, and will be available for 7 years.
Access criteria: We will upload the data to a data repository (ICPSR), and researchers may access it by following the protocols set by the repository.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
Of 885 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 5 months is below that.
Counting every sponsor, half of 962 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.